Morgan Stanley cut its position in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) by 8.9% during the first quarter, Holdings Channel reports. The fund owned 353,301 shares of the specialty pharmaceutical company’s stock after selling 34,703 shares during the period. Morgan Stanley’s holdings in SciClone Pharmaceuticals were worth $3,462,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the company. Airain ltd acquired a new position in shares of SciClone Pharmaceuticals during the first quarter worth $131,000. Navellier & Associates Inc increased its position in shares of SciClone Pharmaceuticals by 9.4% in the first quarter. Navellier & Associates Inc now owns 30,439 shares of the specialty pharmaceutical company’s stock worth $298,000 after buying an additional 2,614 shares during the last quarter. SG Americas Securities LLC increased its position in shares of SciClone Pharmaceuticals by 60.7% in the first quarter. SG Americas Securities LLC now owns 28,047 shares of the specialty pharmaceutical company’s stock worth $275,000 after buying an additional 10,598 shares during the last quarter. American Century Companies Inc. increased its position in shares of SciClone Pharmaceuticals by 0.8% in the first quarter. American Century Companies Inc. now owns 432,067 shares of the specialty pharmaceutical company’s stock worth $4,234,000 after buying an additional 3,549 shares during the last quarter. Finally, Louisiana State Employees Retirement System increased its position in shares of SciClone Pharmaceuticals by 2.4% in the first quarter. Louisiana State Employees Retirement System now owns 21,000 shares of the specialty pharmaceutical company’s stock worth $206,000 after buying an additional 500 shares during the last quarter. Hedge funds and other institutional investors own 73.26% of the company’s stock.

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) remained flat at $11.05 during trading on Friday. 132,160 shares of the company were exchanged. The company has a market capitalization of $576.71 million, a price-to-earnings ratio of 13.63 and a beta of 1.71. SciClone Pharmaceuticals, Inc. has a 52-week low of $8.55 and a 52-week high of $11.43. The company has a 50-day moving average of $10.99 and a 200 day moving average of $10.17.

SciClone Pharmaceuticals (NASDAQ:SCLN) last posted its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.02. SciClone Pharmaceuticals had a net margin of 25.18% and a return on equity of 21.10%. The business had revenue of $44.52 million during the quarter. On average, equities research analysts forecast that SciClone Pharmaceuticals, Inc. will post $0.94 earnings per share for the current fiscal year.

WARNING: This story was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.dailypolitical.com/2017/08/18/sciclone-pharmaceuticals-inc-scln-shares-sold-by-morgan-stanley.html.

Separately, Maxim Group reiterated a “hold” rating on shares of SciClone Pharmaceuticals in a research note on Thursday, June 8th.

In other news, CEO Hong Zhao sold 30,000 shares of SciClone Pharmaceuticals stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $11.00, for a total transaction of $330,000.00. Following the transaction, the chief executive officer now owns 30,000 shares in the company, valued at approximately $330,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Friedhelm Blobel sold 35,044 shares of SciClone Pharmaceuticals stock in a transaction on Friday, June 30th. The stock was sold at an average price of $11.00, for a total transaction of $385,484.00. Following the transaction, the chief executive officer now owns 149,863 shares in the company, valued at approximately $1,648,493. The disclosure for this sale can be found here. In the last ninety days, insiders sold 275,500 shares of company stock valued at $2,919,764. 5.16% of the stock is currently owned by insiders.

About SciClone Pharmaceuticals

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Want to see what other hedge funds are holding SCLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN).

Institutional Ownership by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.